参考文献
[1]Clavel-Chapelon F，Gerber M.Reproductive factors and breast cancer risk.Do they differ according to age at diagnosis?Breast Cancer Res Treat，2002，72(2)：107-115.
[2]Bruzzi P，Negri E，La Vecchia，et al.Short term increase in risk of breast cancer after full term pregnancy[J].BMJ，1988，297(6656)：1096-1098.
[3]Micheli A，Muti P，Secreto G，et al.Endogenous sex hormones and subsequent breast cancer in premenopausal women[J].Int J Cancer，2004，112(2)：312-318.
[4]Ganmaa，M S，Labreche F.Occupational risk factors for female breast cancer：a review.Occup Environ Med，1996，53(3)：145-156.
[5]Xu YL，Sun Q，Shan G L，et al.A case-control study on risk factors of breast cancer in China[J].Arch Med Sci，2012，8(2)：303-309.
[6]Filippini S E，Vega A.Breast cancer genes：beyond BRCA1 and BRCA2[J].Front Biosci(Landmark Ed)，2013，18：1358-1372.
[7]Eisinger F，Sobol H，Serin D，et al.Hereditary breast cancer，circa 1750[J].Lancet，1998，351(9112)：1366.
[8]Figueiredo J C，Brooks J D，Conti D V，et al.Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2：potential modifying effect of BRCA1/BRCA2 mutationcarrier status[J].Breast Cancer Res Treat，2011，127(3)：819-829.
[9]叶静，单保恩.乳腺癌易感基因的研究进展[J].癌症，2002，21(9)：1035-1039.
[10]Antoniou A，Pharoah P D，Narod S，et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutationsdetectedin case Series unselected for familyhistory：a combined analysis of 22 studies[J].Am J Hum Genet，2003，72(5)：1117-1130.
[11]Spearcman A D，Sweet K，Zhou XP，et al.Clinically applicablemedels to characterize BRCA1 and BRCA2 variants of uncertain significance[J].J Clin Oncol，2008，26(33)：5393-5400.
[12]Clegg H，Itahana K，Zhang Y.Unlocking the Mdm22p53 loop：ubiquitin is the key[J].Cell Cycle，2008，7(3)：287-292.
[13]Olivier M，Langerod A，Carrieri P，et al.The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer[J].Clin Cancer Res，2006，12(4)：1157-1167.
[14]Norberg T，Klaar S，Karf G，et al.Increased P53 mutation frequency during tumor progression results from a breast cancer cohor[J].Cancer Res，2001，61(22)：8317-8321.
[15]Parija S，Kumar A.A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer[J].int J Bioinform Res Appl，2011，7(1)：1-14.
[16]岳瑶，李惠平.HER2和AKT与乳腺癌预后研究进展[J].癌症进展，2011，9(3)：271-273.
[17]Piccart-Gebhart M J，Procter M，Leyland-Jones B，et al.Transtuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med，2005，353(16)：1659-1672.(https://www.daowen.com)
[18]Weischer M，Bojesen S E，Ellervik C，et al.CHEK2∗1100delC genotyping for clinical assessment of breast cancer risk：meta-analysesof 26，000 patient cases and 27，000 control[J].J ClinOncol，2008，26(4)：542-548.
[19]Caporali S，Falcinelli S，Starace G，et al.DNA damage inducedby temozolomide signals to both ATM and ATR：role of the mismatchrepair system[J].Mol Pharmacol，2004，66(3)：478-491.
[20]Paglia L L，LaugéA，Weber J，et al.ATM germline mutatuionsin women with familial breast cancer and a relative with haematologicalmalignancy[J].Breast Cancer Res Treat，2010，119(2)：443-452.
[21]Thompson D，Antoniou A C，Jenkins M，et al.Two ATM cariantsand breast cancer risk[J].Hum Mutation，2005，25(6)：594-595.
[22]Lavin M F.ATM and the Mre11 complex combine to recognizeand signal DNA double-strand breaks[J].Oncogene，2007，26(56)：7749-7758.
[23]Heikkinen K，Rapakko K，Karppinen S M，et al.RAD50 and NBS1 are breast cancer susceptibility genes associated with genomicinstability[J].Carcinogenesis，2006，27(8)：1593-1599.
[24]Erkko H，Xia B，NikkiläJ，et al.A recurrent mutation in PALB2 in Finnish cancer families[J].Nature，2007，446(7133)：316-319.
[25]李佳圆，杨非，曾红艳等.CYP1B1基因多态性与乳腺癌关系的病例-对照研究[J].卫生研究，2007，36(5)：596-598.
[26]Wen W，Cai Q，Shu XO，et al.Cytochrome P4501B1 and catechol-Omethyltransferase genetic polymorphisms and breast cancerrisk in Chinese women：results from the Shanghai breast cancerstudy and a meta-analysis[J].Cancer Epidemiol Biomarkers Prev，2005，14(2)：329-335.
[27]Ebeling F G，Stieber P，Untch M，etal.SerumCEA and CA15-3asprognostic factorsinprimary breastcancer.BrJCancer，2002，86：1217-1222.
[28]DeLaL ande B，Hacene K，Floiras J L，et al.Prognosticvalue of CA15.3kinetics formetastatic breast cancer.Int J Biol Markers，2002，17：231-238.
[29]Molia R，Filella X A.Prospecctive，evaluation of CEA and CA15-3inpatients with locoregional breast cancer.Anticancer，2003，23：1035-1041.
[30]李树玲.乳腺肿瘤学[M].北京：科学技术文献出版社，2000：306.
[31]Michels J J，Duigou F，Marnay J.Flowcytometryinprimary breast carcinomas：prognostic impact of proliferative activity[J].Breast Cancer Res Treat，2000，62：117-126.
[32]Silvestrini R，Benini E，Daidone M G，et al.p53asanindependent prognostic marker inlymph-node-negative breast cancer patients[J].JNatlCancerInst，1993，85：965-970.
[33]Rochefort H，Liaudet-Coopman E，Beaujouin M，et al.CathepsinD：newly discovered function-sofalong-standing aspartic proteasein cancer andapoptosis[J].CancerLett，2006，18：167-179.
[34]Miller FR.Xenograft models of premalignant breast disease[J].J Mammary Gland Biol Neoplasia，2000，5(4)：379-391.